Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS(®) (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.

“This newly executed CYFENDUS(®) contract modification with the U.S. government highlights the continued importance of maintaining readiness against anthrax threats,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Emergent remains committed to ensuring access to CYFENDUS(®) and strengthening preparedness through reliable domestic manufacturing and supply.”